title: Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.
abstract: OBJECTIVE
  To study the effects of non-cytotoxic concentrations of docetaxel on some important angiogenic factors of LS174T Cells.
  
  
  METHODS
  The non-cytotoxic concentration of docetaxel and the activity of gelatinase were determined with MTT and gelatin zymography respectively, the expression of VEGF(vascular endothelial growth factor), bFGF (basic fibroblast growth factor), MMP (matrix metalloproteinase) 2 and MMP 9 was investigated with RT-PCR and Western blot.
  
  
  RESULTS
  The maximum non-cytotoxic concentration of docetaxel on LS174T Cells was 1.0 ng/ml. Compared with the solvent control group, 0.1, 0.5, 1.0 ng/ml of docetaxel could downregulate the expression of VEGF, bFGF, MMP 2 and MMP 9 and suppress the activity of gelatinase.
  
  
  CONCLUSIONS
  Our study suggests that the non-cytotoxic concentrations of docetaxel have strong antiangiogenic activity on LS174T Cells, which suggests docetaxel may be a promising antiangiogenic agent.
authors.affiliation: Department of Gastroenterology, Huashan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Xue-Liang
authors.initials: XL
authors.lastname: Guo
authors.forename: Geng-Jin
authors.initials: GJ
authors.lastname: Lin
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Yong
authors.initials: Y
authors.lastname: Gao
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Qian
authors.forename: San-Rong
authors.initials: SR
authors.lastname: Xu
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Fu
authors.forename: Qing
authors.initials: Q
authors.lastname: Xu
authors.forename: Jie-Jun
authors.initials: JJ
authors.lastname: Wang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D000077143:Docetaxel; D016228:Endothelial Growth Factors / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D008222:Lymphokines / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000494:pharmacology*; D043823:Taxoids; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D000077143:Docetaxel; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D017239:Paclitaxel